Targets › TNFSF15
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Immunology; next expected readout Jan 2027.
Cytokine that signals through TNFRSF25 receptor. Functions as a T-cell costimulator, that increases IL-2 responsiveness and secretion of pro-inflammatory cytokines which enhances T-cell activation, proliferation and the survival of activated T-cells. (UniProt, O95150)
Open in Phaseline: the race on TNFSF15, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biocad | BCD-261 Anti-TL1A human monoclonal antibody | TNFSF15, TL1A | Phase 2 | Ulcerative Colitis (UC); Crohn's Disease (CD); Healthy | Jan 2027 |
Ulcerative Colitis (UC) (1) Crohn's Disease (CD) (1) Healthy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.